Postdoctor in Translation Pharmacokinetics/pharmacodynamics

[Ema Shollenberger]

Department of Pharmaceutical Biosciences has 140 employees and a number of visiting researchers and fellow students. The department has twelve research groups with a common administration and we are doing research and teaching in pharmaceutical cell biology / biochemistry, pharmacology, pharmaceutical and drug addiction, pharmacotherapy, pharmacokinetics, pharmacometry, clinical pharmacy, bioinformatics, imaging mass spectrometry, molecular neuropharmacology, immunology, biological drugs / biotechnology as well as toxicology and drug safety. More information about the department and its activities can be found at www.farmbio.uu.se

The postdoctoral fellow will be working in the research group of Translational Pharmacokinetics and Pharmacodynamics (tPKPD; http://www.farmbio.uu.se/research/researchgroups/tPKPD/). The group takes a multidisciplinary approach to improve the understanding of fundamental and functional aspects of PKPD in health and disease, with special focus on drug delivery to the brain. Within this area, the group among other projects addresses translation of PK data from the preclinical to the clinical setting. This is important for optimizing the drug discovery processes and promoting efficient treatment of CNS diseases. We are interested in brain drug delivery in relation to transport processes of both small and large molecules across the CNS barriers including the blood-brain barrier (BBB).

The postdoctoral fellow will focus on evaluating pharmacokinetic aspects of the development of drug neurotoxicity, as a part of the EU IMI2-RIA funded project NeuroDeRisk (Neurotoxicity De-Risking in Preclinical Drug Discovery). Neurotoxicity, i.e., any adverse effect on the central nervous system or peripheral nervous system, is a major issue encountered in clinical phases of drug R&D that at the present stage of science and technology is still poorly predicted in the pre-clinical drug candidate assessment. The NeuroDeRisk consortium will provide novel validated and integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system, and thus help to de-risk drug candidates earlier in the R&D phases. The postdoctoral fellow will be part of the international consortium consisting of 19 academic and industrial partners.

For instructions on how to apply, please refer to: http://bit.ly/2GmD8IG